Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Myelodysplastic Syndromes 3 Colitis 3 Carcinoma, Non-Small-Cell Lung 3 Urogenital Neoplasms 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Leukemia, Biphenotypic, Acute 2 Graft vs Host Disease 2 Neoplasms 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myelomonocytic, Acute 1 Hepatitis 1 Crohn Disease 1

Interventions

Certolizumab Pegol 5 Infliximab 4 Adalimumab 3 Nivolumab 2 MEDI2070 2 vedolizumab 1 secukinumab 1 golimumab 1 cabozantinib 1 Vitamin E 1 Vaccines 1 Ustekinumab 1 Sutures 1 Surgical Instruments 1 Specimen Handling 1 Soybean Oil 1 Saline Solution 1 Ringer's Lactate 1 Pneumococcal Vaccines 1 Platinum Compounds 1 Photoplethysmography 1 Papillomavirus Vaccines 1 Methoxsalen 1 Medical Marijuana 1 Lysine Acetyltransferase 5 1 Iron-Dextran Complex 1 Ipilimumab 1 Indigo Carmine 1 Hydroxyethyl Starch Derivatives 1 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Crohn Disease × vedolizumab × Clear all

NCT02768532 2023-06-15

VEDO-PREDIRESP

Centre Hospitalier Universitaire de Saint Etienne

Phase 4 Terminated

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡